{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:13:02Z","timestamp":1770721982645,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,9,26]],"date-time":"2011-09-26T00:00:00Z","timestamp":1316995200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-2474-12-209","type":"journal-article","created":{"date-parts":[[2011,9,27]],"date-time":"2011-09-27T06:43:55Z","timestamp":1317105835000},"source":"Crossref","is-referenced-by-count":69,"title":["The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women"],"prefix":"10.1186","volume":"12","author":[{"given":"Robert B","family":"Hopkins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Goeree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Pullenayegum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,26]]},"reference":[{"key":"1248_CR1","unstructured":"Osteoporosis Facts and Statistics. [ http:\/\/www.osteoporosis.ca\/index.php\/ci_id\/8867\/la_id\/1.htm ]"},{"key":"1248_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s001980170116","volume":"12","author":"ME Wiktorowicz","year":"2001","unstructured":"Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E: Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int. 2001, 12: 271-278. 10.1007\/s001980170116.","journal-title":"Osteoporos Int"},{"key":"1248_CR3","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1001\/jama.298.23.2761","volume":"298","author":"JA Cauley","year":"2007","unstructured":"Cauley JA, Hochberg MC, Lui LY, Palermo L, Ensrud KE, Hillier TA, Nevitt MC, Cummings SR: Long-term risk of incident vertebral fractures. JAMA. 2007, 298: 2761-2767. 10.1001\/jama.298.23.2761.","journal-title":"JAMA"},{"key":"1248_CR4","first-page":"S14","volume-title":"American Journal of Medicine 122(2 SUPPL)()(pp S14-S21), 2009 Date of Publication: 2009","author":"JP Bilezikian","year":"2009","unstructured":"Bilezikian JP: Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis. American Journal of Medicine 122(2 SUPPL)()(pp S14-S21), 2009 Date of Publication: 2009. 2009, S14-S21."},{"key":"1248_CR5","first-page":"310","volume":"60","author":"M Boers","year":"2002","unstructured":"Boers M: EMEA guidelines for trials in osteoporosis: design implications. Neth J Med. 2002, 60: 310-314.","journal-title":"Neth J Med"},{"key":"1248_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJMsb1006120","volume":"363","author":"CM Stein","year":"2010","unstructured":"Stein CM, Ray WA: The ethics of placebo in studies with fracture end points in osteoporosis. N Engl J Med. 2010, 363: 1367-1370. 10.1056\/NEJMsb1006120.","journal-title":"N Engl J Med"},{"key":"1248_CR7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJMsb1002227","volume":"363","author":"CJ Rosen","year":"2010","unstructured":"Rosen CJ, Khosla S: Placebo-controlled trials in osteoporosis--proceeding with caution. N Engl J Med. 2010, 363: 1365-1367. 10.1056\/NEJMsb1002227.","journal-title":"N Engl J Med"},{"key":"1248_CR8","volume-title":"Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans","author":"Canadian Institutes of Health Research","year":"2010","unstructured":"Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council, Social Sciences and Humanities Research Council of Canada: Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. 2010"},{"key":"1248_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","volume":"326","author":"F Song","year":"2003","unstructured":"Song F, Altman DG, Glenny AM, Deeks JJ: Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003, 326: 472-10.1136\/bmj.326.7387.472.","journal-title":"BMJ"},{"key":"1248_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD: The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997, 50: 683-691. 10.1016\/S0895-4356(97)00049-8.","journal-title":"J Clin Epidemiol"},{"key":"1248_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1017\/S0266462300008928","volume":"6","author":"DM Eddy","year":"1990","unstructured":"Eddy DM, Hasselblad V, Shachter R: A Bayesian method for synthesizing evidence. The Confidence Profile Method. Int J Technol Assess Health Care. 1990, 6: 31-55. 10.1017\/S0266462300008928.","journal-title":"Int J Technol Assess Health Care"},{"key":"1248_CR12","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1185\/03007990903035281","volume":"25","author":"JP Jansen","year":"2009","unstructured":"Jansen JP, Bergman GJ, Huels J, Olson M: Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Curr Med Res Opin. 2009, 25: 1861-1868. 10.1185\/03007990903035281.","journal-title":"Curr Med Res Opin"},{"key":"1248_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semarthrit.2010.06.001","volume":"40","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Bergman GJ, Huels J, Olson M: The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum. 2011, 40: 275-284. 10.1016\/j.semarthrit.2010.06.001.","journal-title":"Semin Arthritis Rheum"},{"key":"1248_CR14","unstructured":"Reference Manager, Version 11 for Windows. Thomson ResearchSoft. Carlsbad, CA, USA. 2009, Carlsbad, CA, USA, Thomson ResearchSoft"},{"key":"1248_CR15","unstructured":"The Bayesian inference Using Gibbs Sampling(BUGS) Project: WinBUGS. [ http:\/\/www.mrc-bsu.cam.ac.uk\/bugs\/winbugs\/contents.shtml ]"},{"key":"1248_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jclinepi.2004.08.010","volume":"58","author":"L Sung","year":"2005","unstructured":"Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA: Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. J Clin Epidemiol. 2005, 58: 261-268. 10.1016\/j.jclinepi.2004.08.010.","journal-title":"J Clin Epidemiol"},{"key":"1248_CR17","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP: Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005, 331: 897-900. 10.1136\/bmj.331.7521.897.","journal-title":"BMJ"},{"key":"1248_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/j.1742-1241.2009.02072.x","volume":"63","author":"SJ Edwards","year":"2009","unstructured":"Edwards SJ, Clarke MJ, Wordsworth S, Borrill J: Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Int J Clin Pract. 2009, 63: 841-854. 10.1111\/j.1742-1241.2009.02072.x.","journal-title":"Int J Clin Pract"},{"key":"1248_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta9260","volume":"9","author":"AM Glenny","year":"2005","unstructured":"Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, Bradburn M, Eastwood AJ: Indirect comparisons of competing interventions. Health Technol Assess. 2005, 9: 1-iv.","journal-title":"Health Technol Assess"},{"key":"1248_CR20","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE: Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004, 23: 3105-3124. 10.1002\/sim.1875.","journal-title":"Stat Med"},{"key":"1248_CR21","unstructured":"Review Manager (RevMan) [Computer program] Version 5.0. 2008, Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration"},{"key":"1248_CR22","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2","year":"2009","unstructured":"Higgins JP, Green S, editors: Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. 2009, The Cochrane Collaboration"},{"key":"1248_CR23","volume-title":"Indirect treatment comparison [computer program]. Version 1.0","author":"G Wells","year":"2009","unstructured":"Wells G, Sultan S, Chen L, Khan M, Coyle D, Wells GA, Sultan SA, Chen L, Khan M, Coyle D: Indirect treatment comparison [computer program]. Version 1.0. 2009, Ottawa, Canadian Agency for Drugs and Technologies in Health"},{"key":"1248_CR24","unstructured":"The Canadian Agency for Drugs and Technologies in Health (CADTH). [ http:\/\/www.cadth.ca\/index.php\/en\/home ]"},{"key":"1248_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009, 151: 264-9. W64","journal-title":"Ann Intern Med"},{"key":"1248_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archinte.163.7.789","volume":"163","author":"BH Ascott-Evans","year":"2003","unstructured":"Ascott-Evans BH, Guanabens N, Kivinen S, Stuckey BG, Magaril CH, Vandormael K, Stych B, Melton ME: Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch Intern Med. 2003, 163: 789-794. 10.1001\/archinte.163.7.789.","journal-title":"Arch Intern Med"},{"key":"1248_CR27","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996, 348: 1535-1541. 10.1016\/S0140-6736(96)07088-2.","journal-title":"Lancet"},{"key":"1248_CR28","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998, 280: 2077-2082. 10.1001\/jama.280.24.2077.","journal-title":"JAMA"},{"key":"1248_CR29","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","volume":"13","author":"SL Greenspan","year":"1998","unstructured":"Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB: Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998, 13: 1431-1438. 10.1359\/jbmr.1998.13.9.1431.","journal-title":"J Bone Miner Res"},{"key":"1248_CR30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995, 333: 1437-1443. 10.1056\/NEJM199511303332201.","journal-title":"N Engl J Med"},{"key":"1248_CR31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/PL00004171","volume":"9","author":"HA Pols","year":"1999","unstructured":"Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ: Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int. 1999, 9: 461-468. 10.1007\/PL00004171.","journal-title":"Osteoporos Int"},{"key":"1248_CR32","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San MJ, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009, 361: 756-765. 10.1056\/NEJMoa0809493.","journal-title":"N Engl J Med"},{"key":"1248_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/BF02242451","volume":"16","author":"GP Lyritis","year":"1997","unstructured":"Lyritis GP, Tsakalakos N, Paspati I, Skarantavos G, Galanos A, Androulakis C: The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study. Clin Rheumatol. 1997, 16: 354-360. 10.1007\/BF02242451.","journal-title":"Clin Rheumatol"},{"key":"1248_CR34","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1210\/jc.82.9.2784","volume":"82","author":"PJ Meunier","year":"1997","unstructured":"Meunier PJ, Confavreux E, Tupinon I, Hardouin C, Delmas PD, Balena R: Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab. 1997, 82: 2784-2791. 10.1210\/jc.82.9.2784.","journal-title":"J Clin Endocrinol Metab"},{"key":"1248_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/BF01623461","volume":"7","author":"ML Montessori","year":"1997","unstructured":"Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K: The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Osteoporos Int. 1997, 7: 52-58.","journal-title":"Osteoporos Int"},{"key":"1248_CR36","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1210\/jcem-66-4-747","volume":"66","author":"R Pacifici","year":"1988","unstructured":"Pacifici R, McMurtry C, Vered I, Rupich R, Avioli LV: Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. J Clin Endocrinol Metab. 1988, 66: 747-753. 10.1210\/jcem-66-4-747.","journal-title":"J Clin Endocrinol Metab"},{"key":"1248_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF01622291","volume":"7","author":"JM Pouilles","year":"1997","unstructured":"Pouilles JM, Tremollieres F, Roux C, Sebert JL, Alexandre C, Goldberg D, Treves R, Khalifa P, Duntze P, Horlait S: Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporos Int. 1997, 7: 213-218.","journal-title":"Osteoporos Int"},{"key":"1248_CR38","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","volume":"322","author":"T Storm","year":"1990","unstructured":"Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990, 322: 1265-1271. 10.1056\/NEJM199005033221803.","journal-title":"N Engl J Med"},{"key":"1248_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199007123230201","volume":"323","author":"NB Watts","year":"1990","unstructured":"Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990, 323: 73-79. 10.1056\/NEJM199007123230201.","journal-title":"N Engl J Med"},{"key":"1248_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0002-9343(98)00029-1","volume":"104","author":"SJ Wimalawansa","year":"1998","unstructured":"Wimalawansa SJ: A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med. 1998, 104: 219-226. 10.1016\/S0002-9343(98)00029-1.","journal-title":"Am J Med"},{"key":"1248_CR41","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","volume":"34","author":"S Adami","year":"2004","unstructured":"Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD: Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone. 2004, 34: 881-889. 10.1016\/j.bone.2004.01.007.","journal-title":"Bone"},{"key":"1248_CR42","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut III","year":"2004","unstructured":"Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004, 19: 1241-1249. 10.1359\/JBMR.040325.","journal-title":"J Bone Miner Res"},{"key":"1248_CR43","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S8756-3282(01)00665-2","volume":"30","author":"P Ravn","year":"2002","unstructured":"Ravn P, Neugebauer G, Christiansen C: Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone. 2002, 30: 320-324. 10.1016\/S8756-3282(01)00665-2.","journal-title":"Bone"},{"key":"1248_CR44","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","volume":"34","author":"R Recker","year":"2004","unstructured":"Recker R, Stakkestad JA, Chesnut CH, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD: Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone. 2004, 34: 890-899. 10.1016\/j.bone.2004.01.008.","journal-title":"Bone"},{"key":"1248_CR45","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999, 282: 637-645. 10.1001\/jama.282.7.637.","journal-title":"JAMA"},{"key":"1248_CR46","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1210\/jc.85.5.1895","volume":"85","author":"I Fogelman","year":"2000","unstructured":"Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY: Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab. 2000, 85: 1895-1900. 10.1210\/jc.85.5.1895.","journal-title":"J Clin Endocrinol Metab"},{"key":"1248_CR47","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999, 282: 1344-1352. 10.1001\/jama.282.14.1344.","journal-title":"JAMA"},{"key":"1248_CR48","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/13697130500118126","volume":"8","author":"MJ Hooper","year":"2005","unstructured":"Hooper MJ, Ebeling PR, Roberts AP, Graham JJ, Nicholson GC, D'Emden M, Ernst TF, Wenderoth D: Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric. 2005, 8: 251-262. 10.1080\/13697130500118126.","journal-title":"Climacteric"},{"key":"1248_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001, 344: 333-340. 10.1056\/NEJM200102013440503.","journal-title":"N Engl J Med"},{"key":"1248_CR50","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1210\/jc.83.2.396","volume":"83","author":"L Mortensen","year":"1998","unstructured":"Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC: Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998, 83: 396-402. 10.1210\/jc.83.2.396.","journal-title":"J Clin Endocrinol Metab"},{"key":"1248_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000, 11: 83-91. 10.1007\/s001980050010.","journal-title":"Osteoporos Int"},{"key":"1248_CR52","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004, 350: 459-468. 10.1056\/NEJMoa022436.","journal-title":"N Engl J Med"},{"key":"1248_CR53","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/art.23461","volume":"58","author":"JY Reginster","year":"2008","unstructured":"Reginster JY, Felsenberg D, Boonen S, ez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C: Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum. 2008, 58: 1687-1695. 10.1002\/art.23461.","journal-title":"Arthritis Rheum"},{"key":"1248_CR54","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001, 344: 1434-1441. 10.1056\/NEJM200105103441904.","journal-title":"N Engl J Med"},{"key":"1248_CR55","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007, 356: 1809-1822. 10.1056\/NEJMoa067312.","journal-title":"N Engl J Med"},{"key":"1248_CR56","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1210\/jc.2006-1404","volume":"92","author":"S Boonen","year":"2007","unstructured":"Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P: Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab. 2007, 92: 1415-1423. 10.1210\/jc.2006-1404.","journal-title":"J Clin Endocrinol Metab"},{"key":"1248_CR57","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1093\/rheumatology\/kem072","volume":"46","author":"R Nixon","year":"2007","unstructured":"Nixon R, Bansback N, Brennan A: The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford). 2007, 46: 1140-1147. 10.1093\/rheumatology\/kem072.","journal-title":"Rheumatology (Oxford)"},{"key":"1248_CR58","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jclinepi.2008.10.001","volume":"62","author":"G Salanti","year":"2009","unstructured":"Salanti G, Marinho V, Higgins JP: A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol. 2009, 62: 857-864. 10.1016\/j.jclinepi.2008.10.001.","journal-title":"J Clin Epidemiol"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-12-209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2474-12-209\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-12-209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,10]],"date-time":"2016-07-10T10:43:21Z","timestamp":1468147401000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-12-209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,26]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-12-209","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,26]]},"article-number":"209"}}